2013 Gutiérrez-González, A.; Belda-Iniesta, C.; Bargiela-Iparraguirre, J.; Domínguez, G.; Alfonso, P. G.; Perona, R.; Sánchez-Pérez, I. Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair. APOPTOSIS. 2013; 18(3): 347-360. Artículo. 3,614 Q2
2013 Galardi-Castilla, M.; Fernández-Aguado, I.; Suárez, T.; Sastre, L. Mef2A, a homologue of animal Mef2 transcription factors, regulates cell differentiation in dictyostelium discoideum. BMC DEVELOPMENTAL BIOLOGY. 2013; 13: 12. Artículo. 2,752 Q2
2013 Conde, E.; Angulo, B.; Izquierdo, E.; Paz-Ares, L.; Belda-Iniesta, C.; Hidalgo, M.; López-Ríos, F. Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. CLINICAL & TRANSLATIONAL ONCOLOGY. 2013; 15(7): 503-508. Artículo. 1,6 Q4
2013 Conde, E.; Angulo, B.; Izquierdo, E.; Muñoz, L.; Suárez-Gauthier, A.; Plaza, C.; Domínguez, N.; Torres, M.; Madrigal, L.; Rubio-Viqueira, B.; Belda-Iniesta, C.; Hidalgo, M.; López-Ríos, F. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. HISTOPATHOLOGY. 2013; 62(4): 609-616. Artículo. 3,301 Q1
2013 Cortés-Sempere, M.; de Miguel, M. P.; Pernía, O.; Rodríguez, C.; Carpeño, J. D.; Nistal, M.; Conde, E.; López-Ríos, F.; Belda-Iniesta, C.; Perona, R.; Ibáñez de Cáceres, I. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. ONCOGENE. 2013; 32(10): 1274-1283. Artículo. 8,559 D1
2012 Cristóbal Belda-Iniesta, Javier de Castro, Enrique Grande, José María Amate, Zuleika Saz-Parkinson. Pharmacoeconomic analysis for K-Ras status-based decisions for first-line therapy of metastatic colorectal cancer therapy in Spain . J CLIN ONCOL. 30, 2012. Póster (pdf 2372 Kb)    
2012 Cristóbal Belda-Iniesta, Javier de Castro, Enrique Grande, José María Amate, Zuleika Saz-Parkinson. Pharmacoeconomic analysis for K-Ras status-based decisions for first-line therapy of metastatic colorectal cancer (mCRC) in Spain. J CLIN ONCOL 30, 2012 Póster (pdf 1881)    
2012 Sereno, M.; Cejas, P.; Moreno, V.; Belda-Iniesta, C.; López, R.; Nistal, M.; Feliu, J.; Carpeño, J. D. ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications. INTERNATIONAL JOURNAL OF ONCOLOGY. 2012; 40(6): 2104-2110. Article. 2,657 Q2
2012 Sastre, L. Clinical implications of the ENCODE project. CLINICAL
& TRANSLATIONAL ONCOLOGY.2012; 14(11): 801-802. Editorial Material.
1,276 Q4
2012 Cejas, P.; López-Gómez, M.; Aguayo, C.; Madero, R.; Moreno-Rubio, J.; Carpeño, J. D.; Belda-Iniesta, C.; Barriuso, J.; García, V. M.; Díaz, E.; Burgos, E.; González-Barón, M.; Feliu, J. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapy. CURRENT CANCER DRUG TARGETS. 2012; 12(2): 124-131. Review. 4  Q2
2012 Lamarca, A.; Hindi, N.; Belda-Iniesta, C.; de Castro, J. Foot pain: uncommon presentation of lung cancer. BMJ CASE REPORTS. 2012; 2012: 1220115360. Article. No tiene No tiene
2012 Casado, E.; García, V. M.; Sánchez, J. J.; del Pulgar, M. T. G.; Feliu, J.; Maurel, J.; Castelo, B.; Rubio, J.; López, R. A. B.; García-Cabezas, M. A.; Burgos, E.; de Castro, J.; Belda-Iniesta, C.; López-Gómez, M.; Gómez-Raposo, C.; Zambrana, F.; Sereno, M.; Fernández-Martos, C.; Vázquez, P.; Lacal, J. C.; González-Barón, M.; Cejas, P. Upregulation of Trefoil Factor 3 (TFF3) after rectal cancer chemoradiotherapy is an
adverse prognostic factor and a potential therapeutic target. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2012; 84(5): 1151-1158. Article.
4,524 D1
2012 Belda-Iniesta, C. Cost-effectiveness, cancer burden and fi nancial crisis: a perfect storm. CLINICAL & TRANSLATIONAL ONCOLOGY. 2012; 14(10): 713-714. Editorial Material. 1,276  Q4
2012 de Molina, A. R.; de la Cueva, A.; Machado-Pinilla, R.; Rodríguez-Fanjul, V.; del Pulgar, T. G.; Cebrián, A.; Perona, R.; Lacal, J. C. Acid Ceramidase as a chemotherapeutic target to overcome resistance to the antitumoral effect of Choline Kinase Alpha inhibition. CURRENT CANCER DRUG TARGETS. 2012; 12(6): 617-624. Review. 4 Q2
2012 Agostini, A.; Mondragón, L.; Bernardos, A.; Martínez-Máñez, R.; Marcos, M. D.; Sancenón, F.; Soto, J.; Costero, A.; Manguán-García, C.; Perona, R.; Moreno-Torres, M.; Aparicio-Sanchís, R.; Murguía, J. R. Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 2012; 51(42): 10556-10560. Article. 13,734  D1
2012 Carrillo, J.; Martínez, P.; Solera, J.; Moratilla, C.; González, A.; Manguán-García, C.; Aymerich, M.; Canal, L.; del Campo, M.; Dapena, J. L.; Escoda, L.; García-Sagredo, J. M.; Martín-Sala, S.; Rives, S.; Sevilla, J.; Sastre, L.; Perona, R. High resolution melting analysis for the identifi cation of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenita. BLOOD CELLS MOLECULES AND DISEASES. 2012; 49(03 aprl): 140-146. Article. 2,259 Q3
2012 Machado-Pinilla, R.; Carrillo, J.; Manguán-García, C.; Sastre, L.; Mentzer, A.; Gu, B. W.; Mason, P. J.; Perona, R. Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain. CLINICAL & TRANSLATIONAL ONCOLOGY. 2012; 14(10): 755-763. Article.  1,276  Q4
2012 Diz-Chaves, Y.; Kwiatkowska-Naqvi, A.; Von Hulst, H.; Pernia, O.; Carrero, P.; García-Segura, L. M. Behavioral effects of estradiol therapy in ovariectomized rats depend on the age when the treatment is initiated. EXPERIMENTAL GERONTOLOGY. 2012; 47(1): 93-99. Article. IF  3,911. Q1
2011 de Castro-Carpeño, J.; Perona, R.; Belda-Iniesta, C. Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race. CLINICAL & TRANSLATIONAL ONCOLOGY. 2011; 13(11): 774-779. Article. 1,327 Q4
2011 Cortés-Sempere, M.; de Cáceres, I. I. MicroRNAs as novel epigenetic
biomarkers for human cancer. CLINICAL & TRANSLATIONAL ONCOLOGY. 2011; 13(6): 357-362. Article.
1,327 Q4
2011 Belda-Iniesta, C.; Pernía, O.; Simo, R. Metformin: a new option
2011; 13(6): 363-367. Article. 
 1,327 Q4
2011 Belda-Iniesta, C.; de Cáceres, I. I.; de Castro, J. Monoclonal antibodies
for medical oncology: a few critical perspectives. CLINICAL
& TRANSLATIONAL ONCOLOGY. 2011; 13(2): 84-87.
 1,327 Q4
2011 Belda-Iniesta, C.; de Castro, J.; Perona, R. Translational Proteomics:
What Can You Do for True Patients? JOURNAL OF PROTEOME
RESEARCH. 2011; 10(1): 101-104. Editorial Material.
 5,113 Q1
2011 Moncho-Amor, V.; de Cáceres, I. I.; Bandrés, E.; Martínez-Poveda,
B.; Orgaz, J. L.; Sánchez-Pérez, I.; Zazo, S.; Rovira, A.; Albanell, J.;
Jiménez, B.; Rojo, F.; Belda-Iniesta, C.; García-Foncillas, J.; Perona,
R. DUSP1/MKP1 promotes angiogenesis, invasion and metastasis
in non-small-cell lung cancer. ONCOGENE. 2011; 30(6): 668-678. Article.
6,373 D1
2011 Perona, R.; López-Ayllón, B. D.; Carpeno, J. D.; Belda-Iniesta, C. A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. CLINICAL & TRANSLATIONAL ONCOLOGY. 2011; 13(5): 289-293. Article 1,327 Q4
2011 Moncho-Amor, V.; Galardi-Castilla, M.; Perona, R.; Sastre, L. The
dual-specificity protein phosphatase MkpB, homologous to mammalian MKP phosphatases, is required for D. discoideum post-aggregative development and cisplatin response. DIFFERENTIATION. 2011; 81(3): 199-207. Article.
2,807 Q3
2011 Feliú, J.; Borrega, P.; León, A.; López-Gómez, L.; López, M.; Castro,
J.; Belda-Iniesta, C.; Barriuso, J.; Martínez, V.; González-Barón, M.
Phase II study of a fixed dose-rate infusion of gemcitabine associated
with erlotinib in advanced pancreatic cancer. CANCER
221. Article.
 2,833 Q2
2011 Casado, E.; García, V. M.; Sánchez, J. J.; Blanco, M.; Maurel, J.; Feliú,
J.; Fernández-Martos, C.; de Castro, J.; Castelo, B.; Belda-Iniesta, C.; Sereno, M.; Sánchez-Llamas, B.; Burgos, E.; García-Cabezas, M. A.; Mancenido, N.; Miquel, R.; García-Olmo, D.; González-Barón, M.; Cejas, P. A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer. CLINICAL CANCER RESEARCH. 2011; 17(12): 4145-4154. Article.
7,742 D1
2011 García, V. M.; Batlle, J. F.; Casado, E.; Burgos, E.; de Castro, J.; Belda,
C.; Barriuso, J.; Sánchez, J. J.; García-Cabezas, M. A.; González-Barón, M.; Cejas, P. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy. COLORECTAL DISEASE. 2011; 13(9): 989-998. Article.
2,927 Q2
2011 Batlle, J. F.; Cuadrado, E.; Castro, J.; Caldes, T.; Belda, C.; Sastre,
J.; Barriuso, J.; Marín, V. M.; Díaz-Rubio, E.; González-Barón, M.
Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study. CHEMOTHERAPY. 2011; 57(2): 138-144. Article. 
1,816 Q3
2011 Sastre, L. New DNA sequencing technologies open a promising
era for cancer research and treatment. CLINICAL & TRANSLATIONAL
ONCOLOGY. 2011; 13(5): 301-306. Article
1,327 Q4
2010 Ibragimova I.; Ibáñez de Cáceres I.; Hoffman A. M.; Potapova, A.; Dulaimi, E.; Al-Saleem, T.; Hudes, G. R.; Ochs, M. F.; Cairos, P. Global reactivation of epigenetically silenced genes in prostate cancer. CANCER PREVENTION RESEARCH. 2010; 3(9): 1084-1092. Article. 4,978
2010 de Cáceres, I. I.; Cortés-Sempere, M.; Moratilla, C.; Machado-Pinilla, R.; Rodríguez-Fanjul, V.; Manguán-García, C.; Cejas, P.; López-Ríos, F.; Paz-Ares, L.; de Castro Carpeno, J.; Nistal, M.; Belda-Iniesta, C.; Perona, R. Identification of drug-sensitive prediction genes by an epigenetic reactivation screen of cisplatin-resistant NSCLC cell lines. ONCOGENE. 2010; 29(11): 1681-12690. Article.  7,414  
2010 Peralta-Sastre, A.; Manguán-García, C.; de Luis, A.; Belda-Iniesta, C.; Moreno, S.; Perona, R.; Sánchez-Pérez, I. Checkpoint kinase 1 modulates sensitivity to cisplatin after spindle checkpoint activation in SW620 cells. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY. 2010; 42(2): 318-328. Article. 4,956
2010 Galardi-Castilla, M.; Garciandía, A.; Suárez, T.; Sastre, L. The Dictyostelium discoideum acaA Gene Is Transcribed from Alternative Promoters during Aggregation and Multicellular Development. PLOS ONE. 2010; 5(10): e13286. Article. 4,411
2010 Perona, R. The Nobel Prize in Physiology or Medicine 2009 "for telomere biology" and its relevance to cancer and related diseases. CLINICAL & TRANSLATIONAL ONCOLOGY. 2010; 12(10): 647-649. Editorial Material. 1,254
2009 Castro-Carpeno,J. D.;Moyano,M. S.;Saenz,E. C.;Belda-Iniesta,C.;Batlle,J. F.;Baron,M. G.. WITHDRAWN:Bevacizumab: a safe and effective treatment in a patient with advanced colorectal cancer and repeated removal of metastases. ANTICANCER DRUGS. 2009; 20 (Special Issue 1): S7-S10 2,230
2009 Belda-Iniesta,C.;Saenz,E. C.;de Castro-Carpeno,J.;Hernandez,E.;Baron,M. G.. WITHDRAWN:Complete and rapid response to FOLFIRI plus bevacizumab in a patient presenting with impaired liver function and poor performance status from colon cancer liver metastases. ANTICANCER DRUGS. 2009; 20 (Special Issue 1): S11-S12 2,230
2009 Sereno Moyano,M.;Casado Saenz,E.;de Castro-Carpeno,J.;Belda-Iniesta,C.. WITHDRAWN:The combination of FOLFOX4 and bevacizumab may enable salvage surgery of unresectable liver metastases in colon cancer. ANTICANCER DRUGS. 2009; 20 (Special Issue 1): S4-S6 2,230
2009 Carrillo, J; Agra, N; Fernandez, N; Pestana, A; Alonso, J. Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth. ANTI-CANCER DRUGS. 2009; 20(7): 527-533 2,230
2009 Ortin, I; Gonzalez, JF; de la Cuesta, E; Manguan-Garcia, C; Perona, R; Avendano, C. Cytotoxicity mechanisms of pyrazino[1,2-b]isoquinoline-4-ones and SAR studies. BIOORGANIC & MEDICINAL CHEMISTRY. 2009; 17(23): 8040-8047 2,822
2009 Feliu, J; Firvida, JL; Castro, J; Madronal, C; Rodriguez-Jaraiz, A; Salgado, M; Belda-Iniesta, C; Casado, E; Garcia-Mata, J; Gonzalez-Baron, M. Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2009; 63(3): 403-409 2,654
2009 Sanchez-Perez, I; Manguan-Garcia, C; Menacho-Marquez, M; Murguia, JR; Perona, R. hCCR4/cNOT6 targets DNA-damage response proteins. CANCER LETTERS. 2009; 273(2): 281-291 3,741
2009 Cortes-Sempere, M; Chattopadhyay, S; Rovira, A; Rodriguez-Fanjul, V; Belda-Iniesta, C; Tapia, M; Cejas, P; Machado-Pinilla, R; Manguan-Garcia, C; Sanchez-Perez, I; Nistal, M; Moratilla, C; de Castro-Carpeno, J; Gonzalez-Baron, M; Albanell, J; Perona, R. MKP1 repression is required for the chemosensitizing effects of NF-kappa B and PI3K inhibitors to cisplatin in non-small cell lung cancer. CANCER LETTERS. 2009; 286(2): 206-216 3,741
2009 Feliu, J; Sereno, M; De Castro, J; Belda, C; Casado, E; Gonzalez-Baron, M. Chemotherapy for colorectal cancer in the elderly: Who to treat and what to use. CANCER TREATMENT REVIEWS. 2009; 35(3): 246-254 5,295
2009 Sanchez-Perez, I; Alonso, PG; Iniesta, CB. Clinical impact of aneuploidy on gastric cancer patients. CLINICAL & TRANSLATIONAL ONCOLOGY. 2009; 11(8): 493-498 1,146
2009 Perona, R. Old proteins harbour unexpected functions. CLINICAL & TRANSLATIONAL ONCOLOGY. 2009; 11(8): 489-490 1,146
2009 Perona, R; Machado-Pinilla, R; Manguan, C; Carrillo, J. Telomerase deficiency and cancer susceptibility syndromes. CLINICAL & TRANSLATIONAL ONCOLOGY. 2009; 11(11): 711-714 1,146
2009 Rojo, F; Gonzalez-Navarrete, I; Bragado, R; Dalmases, A; Menendez, S; Cortes-Sempere, M; Suarez, C; Oliva, C; Servitja, S; Rodriguez-Fanjul, V; Sanchez-Perez, I; Campas, C; Corominas, JM; Tusquets, I; Bellosillo, B; Serrano, S; Perona, R; Rovira, A; Alban. Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin. CLINICAL CANCER RESEARCH. 2009; 15(10): 3530-3539 6,747
2009 Kast RE;.Belda-Iniesta C.. Subverting glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloral hydrate, chloramphenicol or disulfiram during cytotoxic chemotherapy. CURRENT STEM CELL RESEARCH AND THERAPY. 2009; 4(4): 314-317 No tiene
No tiene
2009 Garcia, VM; Cejas, P; Codesido, MB; Batlle, JF; Carpeno, JD; Belda-Iniesta, C; Barriuso, J; Sanchez, JJ; Larrauri, J; Gonzalez-Baron, M; Casado, E. Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE. 2009; 24(7): 741-748 2,102
2009 Hernando, E; Sarmentero-Estrada, J; Koppie, T; Belda-Iniesta, C; de Molina, VR; Cejas, P; Ozu, C; Le, C; Sanchez, JJ; Gonzalez-Baron, M; Koutcher, J; Cordon-Cardo, C; Bochner, BH; Lacal, JC; de Molina, AR. A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas. ONCOGENE. 2009; 28(26): 2425-2435 7,135
2009 Sereno, M; De Castro, J; Belda-Iniesta, C; Garcia-Cabezas, MA; Cejas, P; Casado, E; Barriuso, J; Feliu, J; Larrauri, J. EPO-R Expression Patterns in Resected Gastric Adenocarcinoma Followed by Adjuvant Chemoradiation Treatment. PATHOLOGY & ONCOLOGY RESEARCH. 2009; 15(1): 1-10 1,152
2009 Cejas, P; Lopez-Gomez, M; Aguayo, C; Madero, R; Carpeno, JD; Belda-Iniesta, C; Barriuso, J; Garcia, VM; Larrauri, J; Lopez, R; Casado, E; Gonzalez-Baron, M; Feliu, J. KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis. PLOS ONE. 2009; 4(12): e8199 4,351